



## Webinar

### Malaria Vaccine R&D and Immunization: Lessons Learned and Considerations for Global Health Impact

March 3, 2022; 09:00 – 12:00 EST / 15:00 – 18:00 CET

**Virtual Webinar: Register [here](#)**

#### Purpose

Significant challenges affect the development and implementation of vaccines targeting diseases prevalent in low- and middle-income countries. The first-generation malaria vaccine RTS,S/AS01 is an important advance in combatting a difficult pathogen and illustrates critical obstacles facing the vaccine and immunization communities. Using RTS,S/AS01 as a case study, this webinar will explore lessons learned and discuss vaccine R&D considerations for malaria and other diseases of global health importance prevalent in resource-limited settings.

#### Audience

Scientists, product developers, regulators, policy makers, implementers, and funders interested in malaria vaccine R&D and implementation, and vaccine and immunization priorities for diseases of global health importance.

#### Topics

- RTS,S/AS01 and lessons learned
- Malaria R&D priorities and strategies
- Vaccine development challenges
- Implementation considerations
- Manufacturing and accessibility
- Safety and regulatory concerns
- Resources and global collaboration

Click [agenda](#) for details

#### About GVIRF

The [Global Vaccine and Immunization Research Forum](#), the central forum for research related to [Immunization Agenda 2030](#), brings together the entire vaccine and immunization research community every two years and is organized by the U.S. National Institute of Allergy and Infectious Diseases, the Bill & Melinda Gates Foundation, and the World Health Organization. Between biennial meetings, a series of webinars is also organized to address emerging issues of interest.

**Malaria Vaccine R&D and Immunization  
Lessons Learned & Considerations for Global Health Impact**

**March 3, 2022 9 am-12 pm EDT**

*Virtual Webinar, Register [here](#)*

**09:00 EST**

**Welcome and Introduction**

Lee Hall, Chief, Parasitology and International Program Branch, NIAID, U.S.  
National Institutes of Health (2 mins)

**Opening Remarks: WHO Perspective**

Kate O'Brien, Director, Department of Immunization, Vaccines and Biologicals,  
WHO (5 mins)

Pedro Alonso, Director, Global Malaria Vaccine Programme, WHO (5 mins)

**09:13 EST**

**Session 1: Lessons Learned from a Vaccine Without a Dual Market -- from RTS,S  
Research and Development to Implementation and Distribution**

Moderator: Jean-Luc Bodmer, Senior Program Officer, Bill & Melinda Gates  
Foundation

**RTS,S: Challenges in Development of a Vaccine Without a Dual Market**

Dennis Di Mascio, Director Global Health, Lead, RTS,S Malaria Program, GSK  
(13 mins)

**RTS,S Pilot Implementation Program and Seasonal Use**

Mary J Hamel, Team Lead, Malaria Vaccines, Department of Immunization,  
Vaccines and Biologicals (IVB), WHO (13 mins)

**Implementation and Distribution Considerations**

Rose Jalang'o, Team Lead, Malaria Vaccine Implementation Program, Ministry  
of Health-Kenya

(10 mins)

**09:50 EST**

**Panel discussion: Lessons learned and emerging issues**

David Kaslow, Chief Scientific Officer, PATH (Chair)

Panel members:

Deepali Patel, senior manager, Policy at GAVI;

Krishna Mohan, Executive Director at Bharat Biotech International Limited;

Dennis Di Mascio, Mary Hamel, Rose Jalang'o

**10:30 EST**

**Session 2. Future Malaria Vaccine R&D Considerations**

Moderator: Annie Mo, Senior Program Officer, NIAID, U.S. National Institutes of Health

**Opening Remarks: The Evolving Context of Malaria, and the Need to Rethink Strategic Approaches**

Rose Gana Fomban Leke, Emeritus Professor

of Immunology and Parasitology at the University of Yaounde (5 mins)

**Vaccine Development Paradigms and Challenges: Strategic Consideration for Future Malaria**

**Vaccines**

Ashley Birkett, Global Head of Malaria, Center for Vaccine Innovation and Access (CVIA), PATH (13 mins)

**Technologic Approaches: Technologies for Subunit Malaria Vaccines**

Simon Draper, Professor of Vaccinology and Translational Medicine at Oxford University (10 mins)

**Whole Organism-Based Vaccine Technologies: Challenges & Opportunities**

Kim Lee Sim, Executive Vice President Process Development and Manufacturing, Sanaria Inc.

(10 mins)

**Vaccine R&D Innovation to Ensure Equitable Access**

Nicaise Ndembi, Chief Science Advisor at the Africa Centers for Disease Control and Prevention  
(10 mins)

**11:20 EST**

**Panel discussion: Future Malaria Vaccine R&D Considerations**

Regina Rabinovich, ExxonMobil Scholar in Residence, Harvard TH Chan School of Public Health, Harvard University (Chair)

Panel members:

Umesh Shaligram, Executive Deputy Director, Serum Institute of India;  
Rose Leke, Ashley Birkett, Simon Draper, Kim Lee Sim, Nicaise Ndembi

**Closing Remarks**

Martin Friede, Coordinator, Initiative for Vaccine Research, WHO (2 mins)